Lv41
542 积分 2025-04-25 加入
Postmenopausal Osteoporosis
7天前
已完结
Goal-directed treatment of osteoporosis
7天前
已完结
Making VFA Part of Standard Clinical DXA Assessment for Osteoporosis Care: Recommendations From the International Working Group on DXA Best Practices
7天前
已完结
Pre-treatment bone mineral density and the benefit of pharmacologic treatment on fracture risk and BMD change: analysis from the FNIH-ASBMR SABRE project
7天前
已完结
Relationship Between Bone Mineral Density T-Score and Nonvertebral Fracture Risk Over 10 Years of Denosumab Treatment
7天前
已完结
Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials
8天前
已完结
Treatment-related changes in bone mineral density as a surrogate biomarker for fracture risk reduction: meta-regression analyses of individual patient data from multiple randomised controlled trials
8天前
已完结
Romosozumab Treatment in Postmenopausal Women with Osteoporosis
8天前
已完结
Romosozumab increases bone mineral density in postmenopausal Chinese women with osteoporosis: A randomised phase three study
8天前
已完结
Effect of low-dose alendronate treatment on bone mineral density and bone turnover markers in Chinese postmenopausal women with osteopenia and osteoporosis
8天前
已完结
皖公网安备34019202002308
